Within Life Science and biotech companies, upcoming news flow in the form of price triggers is important for the development of the share price. This
The biotech companies are having difficulties in terms of stock prices, initially driven by rising interest rates and energy prices, and in terms of the
With good prospects for Orviglance(previously known as Mangoral) we expect coming phase 3 data due in H1’2022 will have significant positive impact on the share
Kapital Partner performs or has within the last 12 months performed corporate finance, market relations, investor relations, Certified Adviser or other advisory activities for the following listed companies: NORD.investments, Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.
Del indlægget på sociale media eller på email.